Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12730854 | 0.90 | HTT (0.41) | ELANEHSD11B1MGLLKMT2AHTT | |
| SCHEMBL14817279 | 0.86 | ELANE (0.45) | ELANEKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL14817283 | 0.86 | ELANE (0.45) | ELANEKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL12730890 | 0.86 | HTT (0.40) | ELANEHSD11B1MGLLKMT2AHTT | |
| SCHEMBL12730868 | 0.84 | ELANE (0.40) | ELANEKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL12730864 | 0.82 | POLB (0.44) | ELANEKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL12730865 | 0.81 | MAPT (0.45) | ELANEKMT2ASMN1; SMN2 | |
| SCHEMBL12730862 | 0.81 | PARP15 (0.43) | HSD11B1MGLLTDP1KDM2BEPHX2 | |
| SCHEMBL15250512 | 0.79 | ELANE (0.37) | ELANEKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL15092031 | 0.79 | HTT (0.61) | ELANEHSD11B1MGLLKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404316-B2 | Polymerizable liquid crystal compound and its polymer | JNC CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404316-B2 | Polymerizable liquid crystal compound and its polymer | JNC CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CCNT1, POF1B, CCND3 | ELANE 3245/4885HSD11B1 2112/4885MGLL 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.